Understanding how amyloid beta affects neurons in Alzheimer's disease
Using Chirality to Understand and Control Amyloid Beta Neuronal Uptake and Toxicity
This study is looking at how different forms of a protein called amyloid beta affect brain cells, which is important for finding new treatments for Alzheimer's disease, and it's being done by a team of experts working together to help protect brain health.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Santa Cruz NIH-funded |
| Lab location | 1 site (Santa Cruz, United States) |
| Project ID | NIH-11080284 on NIH RePORTER |
What this research studies
This research investigates the relationship between amyloid beta (Aβ) uptake by neurons and its toxicity, which is crucial for developing treatments for Alzheimer's disease. The team will use advanced techniques to create stable samples of Aβ in different forms and analyze how these forms interact with neurons. By understanding the structural properties of Aβ aggregates, the research aims to identify ways to prevent their harmful effects on brain cells. This collaborative effort involves experts from various fields to ensure a comprehensive approach to the problem.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those at risk of developing it due to genetic or environmental factors.
Not a fit: Patients with other forms of dementia unrelated to amyloid beta pathology may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that mitigate the toxic effects of amyloid beta in Alzheimer's disease.
How similar studies have performed: Previous research has shown promise in understanding amyloid beta's role in Alzheimer's, but this specific chirality-based approach is relatively novel.
Where this research is happening
Santa Cruz, United States
- University of California Santa Cruz — Santa Cruz, United States (Active)
Researchers
- Principal investigator: Raskatov, Jevgenij — University of California Santa Cruz
- Study coordinator: Raskatov, Jevgenij
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.